GlaxoSmithKline Pharmaceuticals Limited (BOM:500660)

BOM:500660 Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan 20, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	403,161	487,432	329,173	224,319	281,714	244,012
Market Cap Growth	6.20%	48.08%	46.74%	-20.37%	15.45%	15.67%
Enterprise Value	382,909	466,472	313,334	211,499	270,099	237,483
Last Close Price	2379.85	2840.33	1885.83	1256.53	1486.11	1262.72
PE Ratio	42.21	52.55	55.80	36.73	16.62	68.13
Forward PE	37.05	49.88	44.16	35.58	42.30	40.93
PS Ratio	10.87	13.00	9.53	6.90	8.59	8.34
PB Ratio	23.61	24.98	18.52	12.88	10.58	16.51
P/TBV Ratio	23.72	25.15	18.77	13.14	10.72	17.01
P/FCF Ratio	56.07	38.48	59.76	50.96	36.30	45.72
P/OCF Ratio	54.24	37.79	56.56	46.33	34.75	42.22
PEG Ratio	2.92	6.49	6.49	1.44	2.17	2.82
EV/Sales Ratio	10.32	12.44	9.07	6.50	8.24	8.12
EV/EBITDA Ratio	31.76	40.47	35.58	26.83	36.36	41.42
EV/EBIT Ratio	33.32	41.86	37.35	28.26	38.65	45.71
EV/FCF Ratio	53.25	36.82	56.89	48.05	34.80	44.50
Debt / Equity Ratio	0.02	0.01	0.01	0.01	0.01	0.02
Debt / EBITDA Ratio	0.03	0.01	0.02	0.02	0.03	0.06
Debt / FCF Ratio	0.05	0.01	0.03	0.04	0.03	0.07
Asset Turnover	1.00	0.98	1.00	0.82	0.85	0.94
Inventory Turnover	2.62	2.81	2.75	2.62	2.55	2.49
Quick Ratio	1.43	1.50	1.45	1.50	1.83	1.02
Current Ratio	1.78	1.79	1.84	1.88	2.18	1.63
Return on Equity (ROE)	56.52%	49.75%	33.53%	27.59%	18.39%	17.42%
Return on Assets (ROA)	19.39%	18.17%	15.24%	11.75%	11.28%	10.39%
Return on Invested Capital (ROIC)	-	-	2875.95%	-	299.81%	55.90%
Return on Capital Employed (ROCE)	57.70%	50.60%	41.30%	37.40%	23.80%	29.50%
Earnings Yield	2.37%	1.90%	1.79%	2.72%	6.02%	1.47%
FCF Yield	1.78%	2.60%	1.67%	1.96%	2.76%	2.19%
Dividend Yield	1.85%	1.48%	1.70%	2.55%	2.02%	2.38%
Payout Ratio	74.49%	80.79%	91.80%	249.80%	29.89%	189.04%
Total Shareholder Return	1.85%	1.48%	1.70%	2.55%	2.02%	2.38%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.